검체 채취 카드 시장 - 예측(2026-2031년)

The specimen collection card market is projected to rise, achieving a 5.34% CAGR, to USD 825.676 million in 2031 from USD 604.468 million in 2025.

The specimen collection cards market comprises specialized, paper-based substrates-most notably filter paper cards like Guthrie cards-designed for the ambient-temperature collection, stabilization, transport, and storage of biological samples. These cards are engineered to absorb and dry small volumes of liquid specimens such as blood, saliva, or urine, preserving analytes (DNA, RNA, proteins, metabolites) for later elution and analysis. As a foundational tool in decentralized diagnostics and biobanking, they bridge the gap between sample origin (patient homes, remote clinics, crime scenes) and centralized laboratory facilities, enabling simplified logistics and stable sample integrity without the need for refrigeration or complex handling.

Market expansion is fundamentally driven by the growing emphasis on accessible, decentralized healthcare diagnostics and expanding forensic capabilities. A primary catalyst is the widespread and established use in public health programs, most significantly in newborn screening (NBS). Mandatory NBS programs across numerous countries for conditions like phenylketonuria (PKU) and congenital hypothyroidism create a consistent, high-volume demand for standardized blood collection cards. This application remains a cornerstone of the market. Concurrently, the field of infectious disease surveillance and testing is a significant growth area. Specimen cards provide a practical solution for collecting samples in resource-limited settings, during outbreaks, or for large-scale seroprevalence studies, particularly for diseases where antibody or nucleic acid stability on the card has been validated.

A parallel and robust driver is the expanding role of forensic science. Law enforcement and forensic laboratories utilize specialized collection cards for the secure preservation of biological evidence from crime scenes, victims, and suspects. The cards' ability to stabilize DNA from blood or saliva at room temperature ensures chain of custody integrity and facilitates transport to central labs for genetic profiling, making them indispensable in modern forensic workflows. Furthermore, the rise of direct-to-consumer wellness testing and therapeutic drug monitoring presents emerging applications that leverage the convenience of at-home sample collection.

Geographically, the Asia-Pacific region is emerging as a high-growth market, propelled by substantial government investments aimed at strengthening national healthcare diagnostic infrastructure and forensic capabilities. Initiatives to expand newborn screening programs, improve infectious disease surveillance networks, and modernize forensic science centers are driving concentrated demand for reliable, high-quality collection materials across the region.

Despite its established utility, the market faces competitive pressures from evolving sample collection technologies. A significant constraint is the development and adoption of alternative collection systems, such as liquid-stabilization tubes, volumetric absorptive microsampling (VAMS) tips, and fully integrated, automated sampling devices. These alternatives often offer advantages in quantitative precision, compatibility with liquid-handling robots, or the ability to stabilize a broader range of analytes. For applications requiring exact volumetric accuracy or high-throughput automated processing, these alternatives can challenge the dominance of traditional filter paper cards, necessitating continuous innovation within the card segment.

The competitive landscape features specialized diagnostics companies and filter paper manufacturers with deep expertise in cellulose chemistry and regulatory requirements for in vitro diagnostics. Competition centers on the card's performance characteristics: uniform absorbency, high elution efficiency, minimal inhibitory substance release, and consistency across production lots. Key differentiators include the availability of pre-printed patient ID fields, barcoding for traceability, and cards pretreated with stabilizers for specific analytes (e.g., RNA, pathogens). Success hinges on providing products that are not only chemically reliable but also integrate seamlessly into the data management and laboratory information systems of large-scale screening programs.

In conclusion, the specimen collection cards market is a mature yet evolving niche within the broader in vitro diagnostics and forensic supplies ecosystem. Its growth is structurally supported by enduring public health programs and expanding applications in decentralized testing. For industry experts, strategic focus must center on enhancing card performance to match the sensitivity demands of next-generation molecular assays, developing integrated solutions that combine collection with digital tracking, and differentiating products for high-growth segments like forensics and at-home testing. The future will involve more specialized cards designed for emerging biomarkers and a greater emphasis on connectivity, ensuring the humble collection card remains a vital, intelligent link in the global chain of diagnostic and forensic analysis. Success depends on maintaining the core advantages of simplicity and stability while innovating to meet the precise quantitative and logistical demands of modern laboratory science.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Specimen Collection Cards Market Segmentation

• By Specimen Type
• Blood
• Saliva
• Urine
• Buccal Cells
• Others
• By Material
• Cellulose-Based
• Fiber-Based
• Others
• By Application
• Newborn Screening (NBS)
• Infectious Disease Testing
• Therapeutic Drug Monitoring
• Biomarker Monitoring
• Others
• By End-User
• Hospitals & Clinics
• Diagnostic Centers
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SPECIMEN COLLECTION CARDS MARKET BY SPECIMEN TYPE

• 5.1. Introduction
• 5.2. Blood
• 5.3. Saliva
• 5.4. Urine
• 5.5. Buccal Cells
• 5.6. Others

6. SPECIMEN COLLECTION CARDS MARKET BY MATERIAL

• 6.1. Introduction
• 6.2. Cellulose-Based
• 6.3. Fiber-Based
• 6.4. Others

7. SPECIMEN COLLECTION CARDS MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Newborn Screening (NBS)
• 7.3. Infectious Disease Testing
• 7.4. Therapeutic Drug Monitoring
• 7.5. Biomarker Monitoring
• 7.6. Others

8. SPECIMEN COLLECTION CARDS MARKET BY END-USER

• 8.1. Introduction
• 8.2. Hospitals & Clinics
• 8.3. Diagnostic Centers
• 8.4. Others

9. SPECIMEN COLLECTION CARDS MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. USA
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. Germany
  • 9.4.2. France
  • 9.4.3. United Kingdom
  • 9.4.4. Spain
  • 9.4.5. Others
• 9.5. Middle East and Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. UAE
  • 9.5.3. Others
• 9.6. Asia Pacific
  • 9.6.1. China
  • 9.6.2. India
  • 9.6.3. Japan
  • 9.6.4. South Korea
  • 9.6.5. Indonesia
  • 9.6.6. Thailand
  • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. QIAGEN
• 11.2. Revvity, Inc.
• 11.3. Eastern Business Forms, Inc.
• 11.4. Ahlstrom
• 11.5. ARCHIMED Life Science GmbH
• 11.6. GenTegra LLC
• 11.7. FortiusBio
• 11.8. CENTOGENE GmbH
• 11.9. F. Hoffmann-La Roche Ltd
• 11.10. Thermo Fisher Scientific Inc.

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key Benefits for the Stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations